A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
← catalyst calendarNCT07174583 · readout ≤ 1,077 d
Sponsored by IDEAYA Biosciences (industry) · IDYA — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
262estimated
Sites
13
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-14 | actual | When the study began enrolling |
| Primary completion | Jul 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Small-cell Lung Cancer
- Neuroendocrine Carcinomas
- Solid Tumor Show to Express DLL3
Interventions
- Drug: IDE849
- Drug: durvalumab — also filed as durvalumab Injection [Imfinzi]
- Drug: IDE161
- Drug: Carboplatin
Primary outcomes
what the primary-completion date above is the date OFPart 1A: Safety and Tolerability of IDE849 (Monotherapy)
measured approximately 4 years total study duration
Part 1B: Safety and Tolerability of IDE849 in Combination with durvalumab or IDE161
measured approximately 4 years total study duration
Part 2: Safety and Tolerability of IDE849 (Monotherapy Dose Expansion)
measured approximately 4 years total study duration
Part 2: Safety and Tolerability of IDE849 in Combination with durvalumab or IDE161 or durvalumab + carboplatin (Dose Expansion)
measured approximately 4 years total study duration
Part 2: Objective Response Rate (ORR) and Investigator Assessment of IDE849 ORR per RECIST 1.1
measured approximately 4 years total study duration
Part 2: Duration of Response (DOR) and Investigator Assessment of IDE849 DOR per RECIST 1.1
measured approximately 4 years total study duration
Permalink · IDYA's whole pipeline · Catalyst calendar · Every registered study · What changed